The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, followin…

Lupus NephritisSystemic Lupus ErythematosusSLE - Systemic Lupus Erythematosus+2 more

~Estimated

~$10 – $8,750

Fate TherapeuticsNCT07570862

Phase 1

Safety and Efficacy of ONTO1 in Lupus

ONT01 is a drug that is being studied for the treatment of Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) and is not approved by the FDA. The purp…

Lupus Nephritis (LN)Lupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IV+5 more

~Estimated

~$10 – $6,250

Hospital for Special Surgery, New YorkNCT07107659